$474.16
1.48% yesterday
Nasdaq, Sep 18, 10:08 pm CET
ISIN
US92532F1003
Symbol
VRTX
Sector
Industry

Vertex Pharmaceuticals Stock price

$474.16
-13.89 2.85% 1M
+62.78 15.26% 6M
+67.27 16.53% YTD
+122.16 34.70% 1Y
+288.49 155.38% 3Y
+299.64 171.69% 5Y
+376.81 387.07% 10Y
Nasdaq, Closing price Wed, Sep 18 2024
-7.10 1.48%
ISIN
US92532F1003
Symbol
VRTX
Sector
Industry

Key metrics

Market capitalization $122.38b
Enterprise Value $117.52b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 11.38
P/S ratio (TTM) P/S ratio 11.86
P/B ratio (TTM) P/B ratio 8.28
Revenue growth (TTM) Revenue growth 10.32%
Revenue (TTM) Revenue $10.32b
EBIT (operating result TTM) EBIT $-391.00m
Free Cash Flow (TTM) Free Cash Flow $-1.18b
Cash position $5.80b
EPS (TTM) EPS $-2.03
P/E forward negative
P/S forward 11.54
EV/Sales forward 11.09
Short interest 1.70%
Show more

Create a Free Account to create an Vertex Pharmaceuticals alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Vertex Pharmaceuticals Stock Analysis

Analyst Opinions

35 Analysts have issued a Vertex Pharmaceuticals forecast:

21x Buy
60%
11x Hold
31%
3x Sell
9%

Analyst Opinions

35 Analysts have issued a Vertex Pharmaceuticals forecast:

Buy
60%
Hold
31%
Sell
9%

Financial data from Vertex Pharmaceuticals

Assets
Dec '23
14,144 14,144
Cash 11,222 11,222
Claims 1,563 1,563
Inventories 739 739
Other current assets Other current assets Current assets 621 621
8,942 8,942
Property, plant and equipment 1,453 1,453
Financial assets 2,596 2,596
Intangible Assets 1,928 1,928
Other fixed assets Other assets Fixed assets 2,965 2,965
Total Assets 23,086 23,086
Liabilities
Dec '23
Equity 17,580 17,580
5,506 5,506
Current liabilities 3,547 3,547
Non-current liabilities 1,959 1,959
Total Capital 23,086 23,086

In millions USD.

Don't miss a Thing! We will send you all news about Vertex Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vertex Pharmaceuticals Stock News

Positive
The Motley Fool
about 15 hours ago
Moderna hopes to win approvals for 10 programs by 2027. Vertex Pharmaceuticals could have multiple new blockbuster drugs on the market over the next few years.
Neutral
Seeking Alpha
one day ago
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Cantor Global Healthcare Conference September 17, 2024 9:10 AM ET Company Participants Susie Lisa - SVP, IR Manisha Pai - Executive Director, IR Conference Call Participants Olivia Brayer - Cantor Fitzgerald Olivia Brayer Joining us this morning at our Cantor Global Healthcare Conference. Really excited to have another year of it.
Neutral
Seeking Alpha
3 days ago
Vertex stock is significantly undervalued due to the underestimated potential of its pain treatment drug, VX-548, which could become a blockbuster. VX-548 has shown to be more effective than placebos and potentially more powerful than NSAIDs and ibuprofen in post-surgery pain relief. VX-548 appears to fill the therapeutic gap between NSAIDs and opioids.
More Vertex Pharmaceuticals News

Company Profile

Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Head office United States
CEO Reshma Kewalramani
Employees 5,400
Founded 1989
Website www.vrtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today